Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FDJF1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, awarded on December 4, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The contract provides a 30-month base period with three 30-month option periods and authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. As a critical pharmaceutical supplier within the federal military medical system, DMS Pharmaceutical Group's established performance across diverse product categories and delivery orders demonstrates its operational capability to fulfill specialized pharmaceutical requirements supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FDJF1?
SPE2DR26FDJF1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FDJF1 worth?
The government has obligated $12,766 on SPE2DR26FDJF1.
Is contract SPE2DR26FDJF1 an order under another contract?
Yes. SPE2DR26FDJF1 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJF1 competed?
The extent of competition for SPE2DR26FDJF1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award